Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvalsATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) for its FemBloc Permanent Birth Control. This approval confirms that FemBloc ...